Skip to main content
News Nöthen 05.2021
Prof. Dr. Markus M. Nöthen (left) - and Jun.-Prof. Dr. Andreas Forstner (right) from the Institute of Human Genetics at the University Hospital Bonn
© Andrea Stein / UKB

News categories: Publication

Largest genetic study to date on bipolar disorder

In cooperation with the University of Bonn, researchers studied a total of 400,000 people

Genetic factors contribute significantly to the development of bipolar disorder. The probably largest analysis to date on the hereditary factors involved has now been published. More than 40,000 affected individuals and 370,000 controls were included in the study; some 320 researchers around the globe were involved. Lead partners for the project included the Icahn School of Medicine, New York, the University of Oslo and the University Hospital Bonn. The results not only provide new insights into the genetic basis of the disease, but also into possible risk factors in living conditions or behavior. They are published in the journal "Nature Genetics".

The name "bipolar disorder" is not a coincidence: The mood of those affected oscillates between two extremes. Sometimes they are so depressed for weeks that they barely manage to go about their daily activities. At other times, there are phases when they feel euphoric and full of energy, frantically pursuing their projects.

Risk factors include early childhood traumas such as abuse or the loss of a parent, but also, for example, a stressful lifestyle or the use of certain drugs. To a large extent, however, bipolar disorder is a matter of genes: Experts estimate the contribution of genetic makeup at 60 to 85 percent. Hundreds of genes are probably involved.

DNA lexicon compared at hundreds of thousands of sites

This greatly improves the understanding of the genetic basis. The international consortium searched the DNA of more than 400,000 participants for abnormalities. By comparing the DNA of their subjects at many hundreds of thousands of sites that occur variably in the population, they were able to identify genetic regions that are thought to contribute to the disease. "In this way, we identified 64 gene loci associated with bipolar disorder," explains Prof. Dr. Markus Nöthen, head of the Institute of Human Genetics and meme of the Cluster of Excellence ImmunoSensation2. "33 of them were previously unknown." The hits thus also provide clues to new therapeutic approaches.

Publication

Niamh Mullins, Andreas J. Forstner et al.: Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, DOI: 10.1038/s41588-021-00857-4

Related news

The human P2X4 receptor

News categories: Publication

A starting point for the development of new pain and cancer drugs

The human P2X4 receptor plays an important role in chronic pain, inflammation and some types of cancer. Researchers at the University of Bonn and the University Hospital Bonn (UKB) have now discovered a mechanism that can inhibit this receptor. The results were recently published in the scientific journal Nature Communications and open up a pathway for the development of new drugs. A study carried out by the University of Bonn and the University Hospital Bonn throws light on how P2X2 can be inhibited. The results have recently been published in Nature Communications.
View entry
Kato research group

News categories: Publication

Ominous false alarm in the kidney

Bonn researchers have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction. In cooperation with Nanyang Technological University Singapore and the University Hospital Würzburg, among others, the study provides an explanation for how a point mutation in the immune receptor RIG-I transforms the body's defense system into a self-destructive force and causes severe organ-specific autoimmune diseases. The results have now been published in the journal Science Immunology.
View entry
News_Proebstel

News categories: Publication

Unique immune signatures to distinguish MOGAD from MS

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body’s immune system mistakenly attacks the protective myelin sheath of nerve fibers in the central nervous system. Although MOGAD induces symptoms similar to multiple sclerosis (MS), its underlying biology appears to be fundamentally different. Understanding these distinctions is crucial for developing effective, disease-specific treatments. A new international study now sheds light on these immune differences.
View entry

Back to the news overview